Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Saved in:
| Title: | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. |
|---|---|
| Authors: | Nanda R; The University of Chicago, Chicago, Illinois., Liu MC; Mayo Clinic, Rochester, Minnesota., Yau C; University of California, San Francisco., Shatsky R; University of California, San Diego., Pusztai L; Yale University, New Haven, Connecticut., Wallace A; University of California, San Diego., Chien AJ; University of California, San Francisco., Forero-Torres A; University of Alabama, Birmingham., Ellis E; Swedish Cancer Center., Han H; Moffitt Cancer Center, Tampa, Florida., Clark A; University of Pennsylvania, Philadelphia., Albain K; Loyola University Chicago Stritch School of Medicine, Maywood, Illinois., Boughey JC; Mayo Clinic, Rochester, Minnesota., Jaskowiak NT; The University of Chicago, Chicago, Illinois., Elias A; University of Colorado, Aurora., Isaacs C; Georgetown University, Washington, DC., Kemmer K; Oregon Health & Science University, Portland., Helsten T; University of California, San Diego., Majure M; University of California, San Francisco., Stringer-Reasor E; University of Alabama, Birmingham., Parker C; The University of Chicago, Chicago, Illinois., Lee MC; Moffitt Cancer Center, Tampa, Florida., Haddad T; Mayo Clinic, Rochester, Minnesota., Cohen RN; The University of Chicago, Chicago, Illinois., Asare S; Quantum Leap Healthcare Collaborative, San Francisco, California., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, California., Hirst GL; University of California, San Francisco., Singhrao R; University of California, San Francisco., Steeg K; University of California, San Francisco., Asare A; Quantum Leap Healthcare Collaborative, San Francisco, California., Matthews JB; University of California, San Francisco., Berry S; Berry Consultants, LLC., Sanil A; Berry Consultants, LLC., Schwab R; University of California, San Diego., Symmans WF; MD Anderson Cancer Center, Houston, Texas., van 't Veer L; University of California, San Francisco., Yee D; University of Minnesota, Minneapolis., DeMichele A; University of Pennsylvania, Philadelphia., Hylton NM; University of California, San Francisco., Melisko M; University of California, San Francisco., Perlmutter J; Gemini Group, Ann Arbor, Michigan., Rugo HS; University of California, San Francisco., Berry DA; Berry Consultants, LLC., Esserman LJ; University of California, San Francisco. |
| Source: | JAMA oncology [JAMA Oncol] 2020 May 01; Vol. 6 (5), pp. 676-684. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Adaptive Clinical Trial |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
